Tag: management report

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

The Group published today the Consolidated Interim Report for II Quarter and 6 Months of 2025 (Unaudited). In the stock exchange notice and in the respective section “Key financials” of the report, it was erroneously stated that the result for the second quarter was a net loss, whereas the actual result was a net profit of EUR 4.3 million.
Therefore, we are publishing again both the corrected notice and the amended report.

The Group published today the Consolidated Interim Report for II Quarter and 6 Months of 2025 (Unaudited). In the stock exchange notice and in the respective section “Key financials” of the report, it was erroneously stated that the result for the second quarter was a net loss, whereas the actual result was a net profit of EUR 4.3 million.
Therefore, we are publishing again both the corrected notice and the amended report.

Unaudited consolidated net profit of the INVL Baltic Farmland amounted to EUR 244,000 for 6 months of 2025 and the revenue was EUR 427,000 (for 6 months of 2024 consolidated net profit was EUR 226,000 and revenue was EUR 402,000).

MANAGEMENT REPORT